AMIRA Therapeutics
We are working hard to bring new targeted therapies to children with soft tissue sarcoma and brain cancer and, potentially, to others who may benefit from our revolutionary therapies.
We exist to make an impact on children with cancer.
Our Candidates
AMI463
Inhibitor of cell adhesion molecule (CAM)-related down-regulation by oncogenes (CDON), a key cell surface glycoprotein in the progression of rhabdomyosarcoma and other soft tissue sarcomas, as well as in various solid tumors.
AMI605
Calcineurin/NFATc (Nuclear Factor of Activated T cells) signaling blocker, whose aberrant activation is involved in the initiation, proliferation, migration, and metastasis of several pediatric cancers, including brain cancers and lymphoblastic leukemia.
“AMI463, our lead candidate, has been Designated Orphan Drug by the EMA“
About Us
Amira Therapeutics is a company inspired by the urgent needs of children with cancer, focused on developing new medicines for people of all ages with life-threatening diseases.
We are a preclinical biotech born in Barcelona (Spain) and we collaborate with the best pediatric hospitals to solve urgent needs in pediatric oncology. But if we see an opportunity where other people can benefit from our treatments, we will pursue it with the same commitment we put in children. So that people of all ages can benefit from our dedication to helping children with cancer.
Amira is a name inspired by the love we feel for our children, our princes and princesses (Amira in various cultures), and how cancer becomes a life-altering moment in our lives. We exist to dramatically change the outlook for families who receive the devastating news of a cancer diagnosis or other life-threatening disease.
Contact Us.
Email Us
info@amiratx.com
Call Us
+34937882300
Office
Parc Científic de Barcelona, Edifici Clúster II, Planta 4, Baldiri Reixac, 4-8. 08028 Barcelona Spain